Bone-Forming Cells With Stable Antigen-Presenting Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immunodeficiency and immunosuppression-related bone diseases lack effective modalities that address both immunological and osteoregenerative needs, with existing bone-forming cells requiring external stimulation for antigen-presenting cell properties.
Innovation Solution
Isolated bone-forming cells, such as osteoblasts and osteocytes, are developed to express HLA-II and display stable antigen-presenting cell properties independently of stimulation, obtained through differentiation from mesenchymal stem cells or bone marrow stromal cells, and used in pharmaceutical compositions with pro-inflammatory cytokines for treating immunodeficiency and immunosuppression-related bone diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If bone-forming cells are used to treat immunodeficiency-related bone diseases, then osteoregenerative effects are achieved, but the cells require external stimulation (IFNγ) to display antigen-presenting cell properties, limiting their effectiveness
Solution Approach 1:
The patent applies preliminary action by pre-differentiating mesenchymal stem cells into bone-forming cells that already express HLA class II molecules before administration. This preliminary differentiation ensures the cells possess antigen-presenting capabilities upon implantation without requiring post-administration stimulation with IFNγ, thereby resolving the contradiction between achieving APC properties and avoiding stimulation complexity
Solution Approach 2:
The invention utilizes parameter changes by modifying the differentiation conditions of mesenchymal stem cells during in vitro culture. Specifically, the patent employs controlled culture conditions (including specific growth factors and cytokines) to induce stable HLA class II expression in the differentiated bone-forming cells, transforming them from a stimulated-dependent state to a constitutively active state
2Reliability
If mesenchymal stem cells are stimulated with IFNγ to express HLA class II, then antigen-presenting cell function is enhanced, but the expression is down-regulated when IFNγ concentration increases, inhibiting APC function
Solution Approach 1:
The patent applies preliminary action by establishing stable HLA class II expression during the in vitro differentiation phase before cell administration. This preliminary establishment of antigen-presenting capabilities ensures consistent and reliable expression in the implanted cells, eliminating the need for post-implantation IFNγ stimulation and avoiding the down-regulation issue that occurs with excessive IFNγ exposure
Solution Approach 2:
The invention employs self-service by engineering bone-forming cells that autonomously express HLA class II molecules without requiring external IFNγ stimulation. The cells self-maintain their antigen-presenting function through constitutive expression, making them independent of external cytokine support and avoiding the paradoxical down-regulation that occurs with high IFNγ concentrations
3Adaptability or versatility
If existing treatments are used for immunosuppression-related bone diseases, then general immunosuppression management is achieved, but specific modalities addressing both immunological and osteoregenerative needs are lacking
Solution Approach 1:
The patent applies universality by developing bone-forming cells that simultaneously possess dual functions: osteoregenerative capacity (bone formation and repair) and immunological function (antigen presentation via HLA class II expression). This multi-functional cell therapy approach replaces the need for separate immunosuppressive medications and osteoregenerative treatments, directly addressing the lack of versatile treatment modalities in current practice
Data Source
Figure 1
Figure 2A(I)~2A(II)
Figure 2A(III)~2B(I)
AI summary
The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of diseases and conditions associated with immunodeficiency or immunosuppression.